Levi & Korsinsky has started an investigation into Regeneron Pharmaceuticals for potentially misleading investors about the results of a clinical trial involving fianlimab and Libtayo. In March 2026, Regeneron's investor relations VP expressed optimism about the trial's outcomes, but in May 2026, the company disclosed the trial failed to meet its primary endpoint, causing a sharp stock decline. The investigation aims to determine if Regeneron violated federal securities laws by not adequately disclosing risks. Investors who suffered losses may seek recovery through legal channels.
Regeneron Pharmaceuticals announced that its Phase 3 melanoma trial combining fianlimab and Libtayo did not meet the primary endpoint against Keytruda, causing the stock to fall more than 10%. Prior optimism from company executives about the trial's ...
The Nasdaq Composite fell 0.68% due to rising 10-year U.S. Treasury yields hitting 4.63%, the highest since February 2025, which increased borrowing costs and made bonds more attractive than stocks. This shift particularly impacted AI-driven tech and...
Regeneron Pharmaceuticals faced a setback as its drugs fianlimab and Libtayo failed to meet endpoints in a phase 3 trial for first-line metastatic melanoma, causing shares to drop. However, this failure is not seen as critical for Regeneron's long-te...
Regeneron Pharmaceuticals' stock fell over 10% following the Phase 3 trial results for their melanoma treatment combining fianlimab and cemiplimab. The trial did not achieve statistical significance for the primary endpoint of progression-free surviv...
Regeneron Pharmaceuticals' phase 3 trial for its melanoma drug fianlimab, combined with cemiplimab, failed to meet the primary goal of significantly improving progression-free survival compared to Merck's Keytruda. Although the combination extended m...
